Jasper Hellweg

Associate Analyst,

Argus Research

  • Associate Analyst, Argus Research
  • Cum Laude Graduate With a Bachelor of Science Degree in Business Administration

About Jasper

At Argus Research, Jasper Hellweg covers growth pharmaceutical, medical technology, and financial technology companies. He received his undergraduate degree from Boston University, graduating cum laude with a bachelor of science degree in business administration with concentrations in entrepreneurship and marketing. Prior to joining Argus, Mr. Hellweg worked in a variety of industries, ranging from investment tradeshow management to musical instrument manufacturing. He started his career at Argus in the research department and has since widened his scope to also include becoming a regular contributor for the Market Movers and Market Digest publications, the Vickers Weekly Insider Report, and Argus' bespoke research on IPOs.

Jasper's Articles

Vertex Pharmaceuticals (VRTX) — founded in 1989 in Cambridge, Massachusetts — develops therapies to address cystic fibrosis and other diseases, explains Jasper Hellweg, an analyst with Argus Research, a leading independent Wall Street research firm.
Founded in 1945 and based in Switzerland, Alcon AG (ALC) is a global provider of ophthalmic surgery and vision care products; previously a subsidiary of Novartis AG (NVS), Alcon became an independent company in April, 2019, recalls Jasper Hellweg, an analyst with Argus Research.
GlaxoSmithKline (GSK), based in London, is a global healthcare company engaged in the discovery, development, manufacture and marketing of pharmaceutical and consumer healthcare products, notes Jasper Hellweg, analyst with Argus Research.
While the coronavirus pandemic has reduced the number of elective surgical procedures and impacted the availability of certain materials, Baxter International Inc. (BAX) has partly offset this impact through its broad product portfolio, asserts Jasper Hellweg, an analyst with Argus Research.